特例承認 against Asutorazeneka K.K.

アストラゼネカ株式会社 (医薬品医療機器等法)

医薬品医療機器等法Ministry of Health, Labour and WelfareAugust 30, 2022

Action summary

Company: Asutorazeneka K.K.Romanized
Original: アストラゼネカ株式会社
Corporate Number: 9120001073652
Governing law: 医薬品医療機器等法
医薬品医療機器等法
Action type: 特例承認
特例承認
Action date: August 30, 2022
Issuing authority: Ministry of Health, Labour and Welfare
厚生労働省

Violation

Machine-translated summary — verify against original

Name of the COVID-19 treatment drug: Evashield Intramuscular Injection Set, Generic names: Tixagevimab (Genetically Modified) and Cilgavimab (Genetically Modified), Applicant: AstraZeneca K.K., Application date: June 9, 2022 (Reiwa 4).

Show original Japanese text

新型コロナウイルス感染症に係る治療薬の販売名：エバシェルド筋注セット、一般名：チキサゲビマブ（遺伝子組換え）及びシルガビマブ（遺伝子組換え）、申請者：アストラゼネカ株式会社、申請日：令和４年６月９日

Source

Original Ministry of Health, Labour and Welfare announcement (in Japanese)

The original Japanese disclosure is the authoritative record.

Watch this company

Get an email when Asutorazeneka K.K. has new enforcement actions or registry changes (representative, address, business status). Sign-in is via a one-time email link — no password.

Language

日本語版を見る (Japanese)

Company info

English name: Asutorazeneka K.K. Romanized
Japanese name: アストラゼネカ株式会社
Corporate Number: 9120001073652
Registered address: 大阪府大阪市北区大深町３番１号

See company profile →

About this recordAggregated and translated from public Japanese government disclosures. The English text is for reference only — authoritative content is the linked Japanese source.